{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:53:08Z","timestamp":1760147588077,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect on hospitalization rates. Methods: For this retrospective, observational study, clinical data were collected in 2021 from outpatients (402) as well as hospitalized patients (350) receiving monoclonal antibodies Bamlanivimab, Casirivimab\/Imdevimab or Etesevimab\/Bamlanivimab. These data were compared with data from a control group of patients not receiving antibodies because admission to the hospital was too late for this therapy. Results: Both groups showed a comparable spectrum of risk factors. Due to the late hospitalization of control patients, a higher frequency of severe symptoms, such as fever, dyspnea, syncope and lower viral load, were observed. CRP and leukocytes counts were also higher in the untreated group. Most importantly, hospitalization time was significantly shorter and the number of deaths was also lower in the treated group. Conclusions: Apparently, the application of anti-SARS-CoV-2 antibodies reduced the work load of our hospital as shown by the shorter hospitalization time and lower number of COVID-19-related deaths.<\/jats:p>","DOI":"10.3390\/idr15010013","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T06:37:59Z","timestamp":1676875079000},"page":"125-131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital"],"prefix":"10.3390","volume":"15","author":[{"given":"Judith","family":"Pannier","sequence":"first","affiliation":[{"name":"Dessau Medical Center and Brandenburg Medical School Theodor Fontane, Auenweg 38, 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2563-0386","authenticated-orcid":false,"given":"Norbert","family":"Nass","sequence":"additional","affiliation":[{"name":"Dessau Medical Center and Brandenburg Medical School Theodor Fontane, Auenweg 38, 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad-Kamal","family":"Yaakoub","sequence":"additional","affiliation":[{"name":"Dessau Medical Center and Brandenburg Medical School Theodor Fontane, Auenweg 38, 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian Michael Maria","family":"Stelzner","sequence":"additional","affiliation":[{"name":"Dessau Medical Center and Brandenburg Medical School Theodor Fontane, Auenweg 38, 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susann","family":"Veit","sequence":"additional","affiliation":[{"name":"Dessau Medical Center and Brandenburg Medical School Theodor Fontane, Auenweg 38, 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Kalomoiri","sequence":"additional","affiliation":[{"name":"Dessau Medical Center and Brandenburg Medical School Theodor Fontane, Auenweg 38, 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Yassine","sequence":"additional","affiliation":[{"name":"Dessau Medical Center and Brandenburg Medical School Theodor Fontane, Auenweg 38, 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Behre","sequence":"additional","affiliation":[{"name":"Dessau Medical Center and Brandenburg Medical School Theodor Fontane, Auenweg 38, 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"ref_1","first-page":"104211","article-title":"Novel Coronavirus: From Discovery to Clinical Diagnostics","volume":"79","author":"Phan","year":"2020","journal-title":"Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis."},{"key":"ref_2","unstructured":"(2023, January 02). WHO Weekly Epidemiological Update on COVID-19\u201421 December 2022. Available online: https:\/\/www.who.int\/publications\/m\/item\/covid-19-weekly-epidemiological-update\u201321-december-2022."},{"key":"ref_3","first-page":"CD013825","article-title":"SARS-CoV-2-Neutralising Monoclonal Antibodies for Treatment of COVID-19","volume":"9","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","article-title":"Monoclonal Antibodies for COVID-19 Therapy and SARS-CoV-2 Detection","volume":"29","author":"Hwang","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"ref_5","first-page":"3","article-title":"Erste klinische Erfahrungen \u00fcber die passive Immunisierung mit monoklonalen SARS-CoV-2-spezifischen Antik\u00f6rpern bei Risikopatienten und -patientinnen in der fr\u00fchen Phase einer SARS-CoV-2-Infektion","volume":"41","author":"Weichel","year":"2021","journal-title":"Epid. Bull."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus Etesevimab in Mild or Moderate COVID-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/jcb.30017","article-title":"Recent Advances in Antibody-Based Immunotherapy Strategies for COVID-19","volume":"122","author":"Esmaeilzadeh","year":"2021","journal-title":"J. Cell. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ajem.2021.07.050","article-title":"Real World Utilization of REGEN-COV2 at a Community Hospital","volume":"50","author":"Ash","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/infdis\/jiab377","article-title":"Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019","volume":"224","author":"Ganesh","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_11","first-page":"e19747","article-title":"Real World Utilization of Bamlanivimab at a Rural Community Hospital","volume":"13","author":"Leavitt","year":"2021","journal-title":"Cureus"},{"key":"ref_12","first-page":"1145","article-title":"Real-World Effectiveness of Casirivimab plus Indevimab in a Dedicated Ambulatory Unit Created for Patients with Early COVID-19 during a Massive Delta Variant Wave","volume":"41","author":"Markowicz","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wynia, M.K., Beaty, L.E., Bennett, T.D., Carlson, N.E., Davis, C.B., Kwan, B.M., Mayer, D.A., Ong, T.C., Russell, S., and Steele, J.D. (2022). Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Chest.","DOI":"10.1016\/j.chest.2022.10.020"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pannier, J., Nass, N., and Behre, G. (2021). Monoclonal Antibodies Therapy for COVID-19\u2014Experiences at a Regional Hospital. medRxiv.","DOI":"10.1101\/2021.09.22.21263488"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ofac172","DOI":"10.1093\/ofid\/ofac172","article-title":"Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 Escape Antibodies Elicited by Omicron Infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jinf.2020.06.067","article-title":"SARS-CoV-2 Detection, Viral Load and Infectivity over the Course of an Infection","volume":"81","author":"Walsh","year":"2020","journal-title":"J. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/s41423-021-00772-y","article-title":"Delta Variant (B.1.617.2) Sublineages Do Not Show Increased Neutralization Resistance","volume":"18","author":"Arora","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/joim.13199","article-title":"Insights into Disparities Observed with COVID-19","volume":"289","author":"Carethers","year":"2021","journal-title":"J. Intern. Med."}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/15\/1\/13\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:36:49Z","timestamp":1760121409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/15\/1\/13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["idr15010013"],"URL":"https:\/\/doi.org\/10.3390\/idr15010013","relation":{},"ISSN":["2036-7449"],"issn-type":[{"type":"electronic","value":"2036-7449"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}